Computational early drug discovery in cancer; Analysing drug high-throughput screens of cancer cell lines and their deep molecular characterisation for biomarker discovery; Investigating putative drug targets with CRISPR depletion screens. Retrieving insights in the disease aetiology of cancer by analysing large patient cohorts; In this purely computational course, we will investigate pharmacogenomic data, which will be harnessed by applying biostatistical and machine learning methods.
- Trainer/in: Ines Hellmann
- Trainer/in: Michael Menden